Muralidharan Anbalagan

Author

Also Known As

A Muralidharan, A R Muralidharan, A. Muralidharan, A. R. Muralidharan, Anbalagan Muralidharan, M. Anbalagan, Murali Anbalagan, Muralidharan Anbalagan

130

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Tulane University Louisiana State University Health Sciences Center New Orleans Louisiana Cancer Research Center University of Louisiana at Monroe Louisiana State University

About

Muralidharan Anbalagan is an author at Tulane University specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	634
2	Natural Sciences	2	2	93
3	Engineering	1	1	37
4	Public Health	1	1	22
5	Biomedical Engineering	1	1	37

Muralidharan Anbalagan

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Human Adipose Tissue-Derived Stromal/Stem Cells Promote Migration and Early Metastasis of Triple Negative Breast Cancer Xenografts Brian G. Rowan, Jeffrey M. Gimble, Mei Sheng, PLoS ONE	2014	166
Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer Robert T. Dauchy, Shulin Xiang, Lulu Mao, Cancer Research Breast Cancer GrowthBreast OncologyRat ModelTumor BiologyEndocrine Oncology	2014	162
Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators Lyndsay V. Rhodes, Chandra R. Tate, H. Chris Segar, Breast Cancer Research and Treatment Breast OncologyEmt Master RegulatorsZeb FamilyPan-dac Inhibitor PanobinostatMedicine	2014	101
Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products Mudit Mudit, Mohammad A. Khanfar, Muralidharan Anbalagan, Bioorganic & Medicinal Chemistry Combinatorial ChemistryMedicinal ChemistryHeterocyclicNatural SciencesMarine Natural Products	2008	68
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer Muralidharan Anbalagan, Latonya Carrier, Seth Glodowski, Breast Cancer Research and Treatment Molecular PharmacologyBreast OncologyMedicineHormonal ReceptorReceptor Tyrosine Kinase	2011	63
Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor Shibu Thomas, Srinivasulu Chigurupati, Muralidharan Anbalagan, Molecular Endocrinology UrologyPerineural InvasionTumor GradeUrokinase-type Plasminogen ReceptorOncogenic Agent	2006	52
Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians Santosh Yadav, Muralidharan Anbalagan, Melody Baddoo, Oncogene	2020	45
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts Muralidharan Anbalagan, Alaa M. Ali, Ryan K. Jones, Molecular Cancer Therapeutics Src KinaseBreast OncologyMedicinePaclitaxel Suppresses GrowthPharmacology	2012	44
Cadherin Switching and Activation of β-Catenin Signaling Underlie Proinvasive Actions of Calcitonin-Calcitonin Receptor Axis in Prostate Cancer Girish V. Shah, Muralidharan Anbalagan, Mitan Gokulgandhi, Journal of Biological Chemistry UrologySignal TransductionPerineural InvasionGenitourinary CancerSignaling Pathway	2008	41
Subcellular Localization of Total and Activated Src Kinase in African American and Caucasian Breast Cancer Muralidharan Anbalagan, Krzysztof Moroz, Alaa M. Ali, PLoS ONE	2012	39

Page 1